



EXPRESS MAIL CERTIFICATE

Date 6/5/02 Label No. 028719463-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

DB Beck
Name (Print)

DB Beck
Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.:



07278
PATENT TRADEMARK OFFICE

Docket No.:0136/OK432US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kwang-Hoe CHUNG et al.

Serial No.: 10/089,473

Filed: March 26, 2002

For: NOVEL PROTEIN DERIVED FROM AGKISTRODON SAXATILIS
EMELIANOV AND PROCESS FOR PREPARING THE SAME

June 5, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)

[X]A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[] B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.

[] C. after (A) and (B) above, but before the mailing date of a final rejection, a notice of allowance, or any other action that closes prosecution, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

[] i. Counsel states that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[] ii. A check for the fee set forth in 1.17(p), presently believed to be \$180, is enclosed.

[] D. after (A), (B) and (C) above, but before payment of the issue fee: Counsel states that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS; or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[] i. A check for the fee set forth in 1.17 (p), presently believed to be \$180, is enclosed.

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each

document listed is attached, except as explained below.

(check boxes A and/or B and fill in blanks, if appropriate.)

- A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- B. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

[SERIAL NO. & FILING DATE].

Applicant Identifies these documents by attaching hereto copies of the forms PTO-892 and PTO- 1449 from the files of the prior application(s) or a fresh PTO- 1449 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

3. Document(s) 2 are not in the English language. In accordance with 1.98(c), Applicant states:

- An English translation of the abstract of document(s) 2 or a copy of each corresponding English-language patent or application is enclosed.
- A concise explanation of the relevance of document(s) is found in the attached search report (see MPEP § 609 A(3)x).
- A concise explanation of the relevance of document(s) _____ is set forth as follows: [Insert concise explanation of relevance]
- A concise explanation of the relevance of document(s) _____ can be found on page(s) of the document.
- A concise explanation of document(s) _____ can be found on the attached sheet.

4. No explanation of relevance is necessary for documents in the English language (see MPEP § 609 A(3)).

[X] 5. Other information being provided for the examiner's consideration follows:

A copy of the International Search Report for the corresponding International Application No. PCT/KR00/00809, which was mailed on May 30, 2001.

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

CROSS REFERENCE UNDER 37 C.F.R. §1.78 TO RELATED APPLICATIONS

Pursuant to 37 C.F.R. § 1.79, Applicant notes that the above-identified patent application may be related to the following U.S. Patent Applications:

(1) U.S. Patent Application Serial No. _____, filed _____.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,


S. Peter Ludwig
Attorney for Applicant(s)
Registration No.25,351

DARBY & DARBY P.C.
Post Office Box 5257
New York, N.Y. 10150-5257
(212) 527-7700

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 0136/OK432 SERIAL NO: 10/089,473
 APPLICANT: Kwang Hoe Chung, et al. FILING DATE: March 26, 2002
 CONFIRMATION NO:

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
	1. 6,013,625	1/11/2000	Pierschbacher et al.	514/9		10/12/1994

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES</u>	<u>NO</u>
	2. KR 1997-006318		KR	C07K	14/435	abstract	

OTHER REFERENCES(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)*EXAMINER INITIALS

3. Kang, In-Cheol et al., A Novel Disintegrin Salmosin Inhibits Tumor Angiogenesis, *Cancer Res.*, 59:3754-3760 (1999)
4. Park, Dongsu et al., Cloning and Characterization of Novel Disintegrins from *Agkistrodon halys* Venom, *Mol. Cells*, 8(5):578-584 (1998)
5. Kang, in-Cheol et al., Suppressive Mechanism of Salmosin, a Novel Disintegrin in B16 Melanoma Cell Metastasis, *Biochemical and Biophysical Research Communications.*, 275(1):169-173 (2000)
6. Hong, Sung-Yu et al., Snake Venom Disintegrin, Saxatilin, Inhibits Platelet Aggregation, Human Umbilical Vein Endothelial Cell Proliferation, and Smooth Muscle Cell Migration, *Thrombosis Res.*, 105:79-86 (2002)

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 0136/OK432 SERIAL NO: 10/089,473
APPLICANT: Kwang Hoe Chung, et al. FILING DATE: March 26, 2002
 CONFIRMATION NO:

*EXAMINER
INITIALS

7. Koh, You-Seok et al., Biochemical Characterization of a Thrombin-like Enzyme and a Fibrinolytic Serine Protease from Snake (*Agkistrodon saxatilis*) Venom, *Toxicon*, 39:555-560 (2001)

8. Matsui, Taei et al., Purification and Amino Acid Sequence of Halystase from Snake Venom of *Agkistrodon halys blomhoffii*, a Serine Protease that Cleaves Specifically Fibrinogen and Kininogen, *Eur. J. Biochem.*, 252:569-575 (1998)

9. Kang, In-Cheol et al., Purification and Molecular Cloning of a Platelet Aggregation Inhibitor from the Snake (*Agkistrodon Halys Brevicaudus*) Venom, *Thrombosis Res.*, 91:65-73 (1998)

EXAMINER: _____

DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.